The great pharmacare debate: An ‘overly simplistic’ solution or needed system rationalization?
Source: Benefits Canada | Author: Michael McKiernan | January 10, 2018
From the article:
“It sounds like a lovely solution,” Julia Brown, vice-president of government affairs and market access at Janssen Inc…. But it is “overly simplistic in its approach to what is a very complex health-care, drug reimbursement and patient environment,” she added.
But on the same panel, public policy professor Marc-André Gagnon countered that a consistent national formulary was a crucial component of a new system for pricing drugs.
